Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
Radiation Protection Dosimetry
|
March 13, 2026
Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach
Jehangir Khan, Tobias Rydén, Martijn van Essen, et al.
The International Journal of Cardiovascular Imaging
|
November 28, 2015
18F-FDG PET/CT in the diagnosis of prosthetic valve endocarditis
Erika Fagman, Martijn van Essen, Johan Fredén Lindqvist, et al.
The American Journal of Emergency Medicine
|
August 8, 2012
Unnecessary surgery for acute abdomen secondary to angiotensin-converting enzyme inhibitor use
Laura C G de Graaff, Martijn van Essen, Eleonora M Schipper, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 29, 2011
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate
Saima Khan, Eric P Krenning, Martijn van Essen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 24, 2019
Bone Marrow Absorbed Doses and Correlations with Hematologic Response During <sup>177</sup>Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
Linn Hagmarker, Johanna Svensson, Tobias Rydén, et al.
Nature Reviews. Endocrinology
|
June 3, 2009
Peptide-receptor radionuclide therapy for endocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Clinical Nuclear Medicine
|
December 14, 2011
Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors
Samer Ezziddin, Holger Lauschke, Michael Schaefers, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 12, 2008
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Martijn van Essen, Eric P Krenning, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 30, 2007
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
Martijn van Essen, Eric P Krenning, Willem H Bakker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2010
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
Radiation Protection Dosimetry
|
March 13, 2026
Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach
Jehangir Khan, Tobias Rydén, Martijn van Essen, et al.
The International Journal of Cardiovascular Imaging
|
November 28, 2015
18F-FDG PET/CT in the diagnosis of prosthetic valve endocarditis
Erika Fagman, Martijn van Essen, Johan Fredén Lindqvist, et al.
The American Journal of Emergency Medicine
|
August 8, 2012
Unnecessary surgery for acute abdomen secondary to angiotensin-converting enzyme inhibitor use
Laura C G de Graaff, Martijn van Essen, Eleonora M Schipper, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 29, 2011
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate
Saima Khan, Eric P Krenning, Martijn van Essen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 24, 2019
Bone Marrow Absorbed Doses and Correlations with Hematologic Response During <sup>177</sup>Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
Linn Hagmarker, Johanna Svensson, Tobias Rydén, et al.
Nature Reviews. Endocrinology
|
June 3, 2009
Peptide-receptor radionuclide therapy for endocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Clinical Nuclear Medicine
|
December 14, 2011
Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors
Samer Ezziddin, Holger Lauschke, Michael Schaefers, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 12, 2008
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Martijn van Essen, Eric P Krenning, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 30, 2007
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
Martijn van Essen, Eric P Krenning, Willem H Bakker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2010
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Page
of 4